- Home
- Equipment
- usa massachusetts
- gene editing and therapy
Show results for
Refine by
Gene Editing And Therapy Equipment Supplied In Usa Massachusetts
15 equipment items found
Manufactured by:Obsidian Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Engineered with membrane-bound IL15, Eliminates toxic IL2 regimen, increasing patient accessibility to TIL therapy, Drives improved persistence, IL15 expression controlled by acetazolamide (ACZ), via cytoDRiVE® ...
Manufactured by:MaxCyte. based inWaltham, MASSACHUSETTS (USA)
GUIDE-seq and ONE-seq are used to nominate potential off-target editing sites in cellular models and free DNA, respectively. ONE-seq has the advantages that it can be used to assess adenine and cytosine base editors, it allows variant-aware analysis of multiple genomes simultaneously (thousands), and it detects a broader spectrum of off-target sites. Target cells or tissues are then tested to ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
ImmTOR has significant potential to mitigate unwanted immune responses and induce AAV-specific tolerance to enable redosing of gene therapies. ImmTOR has the potential to administer multiple low doses to achieve therapeutic benefit without risk of overdosing, the ability to treat patients typically excluded from these treatments and is a novel approach to treating systemic diseases ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Selecta’s wholly owned gene therapy program for the treatment of ornithine transcarbamylase (OTC) deficiency is expected to enter the clinic in 2022. OTC deficiency is a genetic disorder urea cycle that causes ammonia to accumulate in the blood. The most severe form of the disorder presents within the first few days of life. Severe symptoms include inability to control body temperature and ...
Manufactured by:Diagnosys LLC based inLowell, MASSACHUSETTS (USA)
The DiagnosysFST®, Full-field Stimulus Threshold, module uses the ColorDome™or ColorFlash™ stimulator. It measures the sensitivity of the visual field by testingfor the lowest luminance flash which elicits a visual sensation perceived by thesubject. The test is run on either dark- or light-adapted patients for one or botheyes in an automated routine to measure a reliable ...
Manufactured by:Novo Nordisk A/S based inBagsværd, DENMARK
Our proprietary GalXC technology leverages a naturally occurring biologic process, ribonucleic acid interference, RNAi, to create therapies that silence disease-causing genes. This platform enables Dicerna to create molecules that can effectively interfere with the RNAi processes that lead to defective or misregulated proteins that cause disease. ...
Manufactured by:Editas Medicine based inCambridge, MASSACHUSETTS (USA)
In fact, we are at an inflection point where we are seeing the first real genomic medicines emerge to help patients. Advances in the scientific fields of cell therapy and gene therapy have paved the way for the success of gene editing, which in turn is now expanding and accelerating the development of a new class ...
by:Dyno Therapeutics based inWatertown, MASSACHUSETTS (USA)
Our CapsidMap™ platform uses AI to systematically and rapidly optimize AAV capsids, overcoming the limitations of naturally occurring virus capsids by improving targeting ability, payload size, immune evasion and manufacturability. By building a massive and detailed map of synthetic AAV capsid sequence space, we can quickly navigate the landscape to find enhanced gene therapy vectors with ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Selecta’s first ImmTORTM + gene therapy candidate MMA-101 for methylmalonic acidemia (MMA) is expected to enter clinical trials the end of 2021. MMA is a rare metabolic disease that may lead to metabolic acidosis and hyperammonemia and is associated with long-term complications including feeding problems, developmental delay, intellectual disability, and chronic kidney ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Selecta Biosciences’ immune tolerance platform, ImmTOR, is designed to give rise to antigen-specific immunity, mitigating unwanted immune ...
Premium
Manufactured by:AB Sciex LLC based inFramingham, MASSACHUSETTS (USA)
Perform consistent and compliant biotherapeutics characterization faster than ever. With the PA 800 Plus system, you can confidently safeguard the success of your biologics. Run multiple characterizations from a single system that biopharma labs depend on, and produce qualitative and quantitative analyses, with speed and ...
Manufactured by:Cytena based inFreiburg, GERMANY
Faster than Ever Before: By automating labor-intensive and time-consuming steps, the F.SIGHT 2.0 significantly streamlines Cell Line Development (CLD), Cell & Gene therapy, as well as Single-cell Omics workflows. The F.SIGHT 2.0 is the fastest single-cell dispenser that isolates both unlabeled and green fluorescent cells. With our patented, highly efficient and gentle single-cell technology, ...
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
Genome editing is efficient, precise and scalable. CRISPR/Cas9 genome editing can make permanent, precisely targeted changes in patients’ chromosomes and repair the underlying genetic mutation, whereas more traditional gene therapy typically involves introducing a non-permanent copy of a gene into ...
Manufactured by:BTX - Harvard Bioscience, Inc. based inHolliston, MASSACHUSETTS (USA)
The AgilePulse In Vivo System, used for animal immunization, vaccine development, and gene therapy, provides an intra-muscular, intra-dermal, or intra-tumor electroporation solution to produce maximum transfection efficiency. Traditional in vivo nucleic acid delivery systems, such as gene gun delivery, suffer from poor efficiency. The AgilePulse In Vivo System effectively introduces DNA or RNA ...
Manufactured by:Fractyl Health based inLexington, MASSACHUSETTS (USA)
Our lead product candidate, the Revita DMR System, or Revita®, is a first-in-class procedural therapy designed to target the duodenum as a root cause of type 2 diabetes. For people with advanced type 2 diabetes, the main form of therapy to control HbA1c today is insulin dose escalation and lifestyle interventions. We have developed and are investigating Revita DMR with the goal of providing ...